Molecular characterization of the mycobacterial heparin-binding hemagglutinin, a mycobacterial adhesin

Franco D. Menozzi; Rainer Bischoff; Emmanuelle Fort; Michael J. Brennan; Camille Locht

doi:10.1073/pnas.95.21.12625

New Research In

Communicated by John B. Robbins, National Institute of Child Health and Human Development, Bethesda, MD (received for review August 11, 1997)

Abstract

Although it generally is accepted that the interaction of Mycobacterium tuberculosis with alveolar macrophages is a key step in the pathogenesis of tuberculosis, interactions with other cell types, especially epithelial cells, also may be important. In this study we describe the molecular characterization of a mycobacterial heparin-binding hemagglutinin (HBHA), a protein that functions as an adhesin for epithelial cells. The structural gene was cloned from M. tuberculosis and bacillus Calmette–Guérin, and the sequence was found to be identical between the two species. The calculated M_r was smaller than the observed M_r when analyzed by SDS/PAGE. This difference can be attributed to the Lys/Pro-rich repeats that occur at the C-terminal end of the protein and to a putative carbohydrate moiety. Glycosylation of HBHA appears to protect the protein from proteolytic degradation, which results in the removal of the C-terminal Lys/Pro-rich region responsible for binding of HBHA to sulfated carbohydrates. Evidence suggests that glycosylation is also important for HBHA-mediated hemagglutination and for certain immunologic properties of the protein. Finally, the absence of a signal peptide in the coding region of HBHA raises the possibility that this protein is not secreted via the general secretion pathway.

Infection by the members of the Mycobacterium tuberculosis complex still remains an important cause of morbidity and mortality worldwide. Tuberculosis causes about 3 million annual deaths, and 8–10 million new cases are reported yearly (1). In addition to being a threat to human health, mycobacterial diseases also have a serious economical impact because of their importance in veterinary medicine. Other mycobacterial species, such as the members of the M. avium/intracellulare complex now are recognized as frequent opportunistic agents infecting immunocompromised individuals (2).

Specific interactions with pulmonary macrophages have been recognized as an important step in the pathogenesis of tuberculosis. Early interactions with other cells or with the extracellular matrix are less well documented, although binding to and invasion of HeLa cells by M. tuberculosis have been known since 1957 (3). More recently, it has been suggested that attachment of mycobacteria to epithelial cells and to extracellular matrix is related to virulence and to extrapulmonary dissemination of tubercle bacilli (4–7). Whereas binding of mycobacteria to macrophages involves mannose receptors and integrins such as the complement receptors (8–10), attachment to epithelial cells appears to occur through interactions with sulfated glycoconjugates (11). Similar to other pathogenic bacteria (12–16), viruses (17–19), or parasites (20–22), M. tuberculosis and M. bovis express on their surface a heparin-binding hemagglutinin (HBHA), which is involved in attachment of the mycobacteria to epithelial cells (11). This 28-kDa protein also induces bacterial auto-aggregation, and patients with active tuberculosis produce antibodies against HBHA, indicating that the HBHA-encoding gene is expressed during the course of mycobacterial infections.

We describe here the cloning of the gene coding for HBHA from M. bovis bacillus Calmette–Guérin (BCG) and M. tuberculosis and the partial characterization of the gene product. We provide evidence that HBHA is a bacterial glycoprotein and that glycosylation may be crucial for the stability of the protein and for some of its immunologic properties. Although HBHA is a surface-exposed protein, the structural gene does not encode an amino-terminal signal sequence, suggesting a sec-independent mechanism of export. Finally, the domain responsible for the interactions of the protein with sulfated glycoconjugates was localized to the C-terminal region, which is composed of lysine-rich repeats.

MATERIALS AND METHODS

Bacterial Strains, Growth Conditions, and DNA Manipulations.

Growth conditions for M. bovis BCG (strain 1173P2; World Health Organization, Stockholm, Sweden) and M. tuberculosis strains have been described elsewhere (11). M. tuberculosis H37Rv and H37Ra came from the culture collection of the Institut Pasteur. Briefly, the mycobacteria were cultured at 37°C in static conditions using 175-cm² Roux flasks that contained 150 ml of Sauton medium supplemented with Triton WR1339. All cloning steps were performed in Escherichia coli XL1-Blue (New England Biolabs) grown in Luria–Bertani broth (23). After transformation with pKK388–1 (CLONTECH), pUC18 (Boehringer Mannheim), or derivatives of these plasmids, antibiotic-resistant E. coli XL1-Blue was selected with ampicillin (150 μg/ml). Restriction enzymes, T4 DNA ligase, and other molecular biology reagents were purchased from Boehringer Mannheim, New England Biolabs, or Promega and were used as recommended by the suppliers. All DNA manipulations were carried out as described by Sambrook et al. (23). PCRs were performed in a Perkin–Elmer thermal cycler model 480 using 50 ng of mycobacterial chromosomal DNA and 1 μg of each primer (Table 1). DNA sequences were determined by using the dideoxy chain-termination method (24). Mycobacterial chromosomal DNA was prepared as described by Baulard et al. (25).

View this table:

Table 1

Oligonucleotide sequences

Production of Recombinant HBHA in E. coli.

E. coli XL1-Blue transformed with pKK-HBHA, a pKK388–1 derivative containing the HBHA-encoding gene under the control of the trc promoter, was grown at 37°C in 500 ml of Luria–Bertani broth supplemented with 150 μg/ml of ampicillin. At an OD₆₀₀ of 0.5, isopropyl β-d-thiogalactoside (IPTG) was added at a final concentration of 1 mM, and incubation was continued for 5 hr. The cells then were harvested by centrifugation at 7,000 × g for 15 min at 4°C and stored at −20°C until further use.

Purification of Recombinant HBHA by Heparin-Sepharose Chromatography.

Frozen IPTG-induced E. coli XL1-Blue(pKK-HBHA) cells from a 500-ml culture were thawed and then resuspended in 15 ml of PBS (pH 7.4) containing 1 mM 4-(2-aminoethyl)-benzenesulfonyl fluoride (AEBSF) (Pefabloc SC, Boehringer Mannheim). The bacteria were sonicated for 4 min at 4°C using a Branson Sonifier at an output of 5 delivered to a microtip, and the lysate was centrifuged at 10,000 × g for 15 min at 4°C. The supernatant was diluted to 200 ml with PBS containing 1 mM AEBSF and then applied onto a heparin CL-6B (Pharmacia) column (1 × 4 cm), previously equilibrated with 100 ml of PBS. The bound material was eluted with a 0–500 mM NaCl linear gradient in PBS containing 1 mM AEBSF (11). All chromatographic steps were carried out at 4°C using a flow rate of 1.5 ml/min.

SDS/PAGE Analysis.

SDS/PAGE was performed as described by Laemmli (26) by using a 4% stacking gel and a 12.5% or 15% separating gel, as indicated. Before electrophoresis, samples were mixed with one-third (vol/vol) of solubilization buffer (6% SDS/15% β-mercaptoethanol/30% glycerol/0.005% bromophenol blue in 0.18 M Tris⋅HCl, pH 6.8) and heated at 95°C for 5 min. After electrophoresis, the gels were stained with Coomassie brilliant blue R-250 (ICN).

Protein Sequencing.

The M. bovis BCG HBHA was purified by heparin-Sepharose chromatography as described (11). Twenty-five micrograms of the purified protein were subjected to SDS/PAGE on a 15% polyacrylamide gel. After electrophoresis, the protein was digested by trypsin within the gel, and the resulting peptides were separated by using reverse-phase HPLC. Four major peptides were isolated and subjected to automated Edman degradation.

Determination of the Carbohydrate Content of HBHA.

Determination of the carbohydrate content of HBHA was performed at the Carbohydrate Research Center at the University of Georgia. Purified M. bovis BCG HBHA was subjected first to preliminary aqueous hydrolysis (2 M trifluoroacetic acid for 2 hr at 105°C), and the liberated monosaccharides were converted to methyl glycosides with anhydrous methanolic HCl (1 M, 80°C for 16 hr), followed by N-acetylation by treatment with methanol, pyridine, and acetic anhydride for 6 hr at room temperature. The methyl glycosides then were treated with trimethylsilane (TMS) reagent (Tri-Sil, Pierce) to form TMS derivatives, as described (27, 28). GC/mass spectrophotometry analysis was performed on a 30-m DBl fused silica capillary column using a Hewlett Packard 5890 GC coupled to a 5970 mass spectrophotometer detector.

Other Techniques.

Immunoblot analyses were performed by electrotransfer onto a poly(vinylidene difluoride) membrane (ProBlott; Applied Biosystems) using the method of Towbin et al. (29). Antigen-antibody complexes were detected by using the ProtoBlot Alkaline Phosphatase System (Promega). Mouse polyclonal anti-HBHA antibodies were produced as described for the production of rat anti-HBHA antibodies (11), and mABs 4057D2 and 3921E4 were a kind gift from D. Rouse and S. Morris [Center for Biologics Evaluation and Research (CBER), Bethesda, MD] (30). Protein concentrations were determined by the method of Bradford (31), using BSA (Sigma) as a standard. Hemagglutination was carried out as described by Menozzi et al. (11).

RESULTS

Cloning and Sequencing of the M. bovis BCG HBHA-Encoding Gene.

A PCR approach was chosen to clone the HBHA-encoding gene of M. bovis BCG, based on peptide sequences of tryptic fragments of the purified protein. After digestion of purified HBHA with trypsin, four peptides were isolated by HPLC, and their amino-terminal sequences were determined (Table 2). The sequences of two peptides, S1441 and S1443, showed the least redundancy of the genetic code, and two pairs of oligonucleotides were designed and named S1441/S1441 reverse and S1443/S1443 reverse, respectively (see Table 1 for the oligonucleotide sequences). Because mycobacterial DNA has a high GC content (32), guanosine and cytosine were favored at the third codon position during the oligonucleotide synthesis. Two PCRs then were carried out by using 50 ng of chromosomal BCG DNA and oligonucleotides S1443 and S1441 reverse (1 μg each) or oligonucleotides S1443 reverse and S1441 (1 μg each). At an annealing temperature of 50°C and after 30 amplification cycles, only the PCR primed with oligonucleotides S1441 and S1443 reverse resulted in the amplification of a distinct DNA fragment, which had an approximate size of 150 bp (not shown). This fragment was amplified when the annealing temperature was increased to 57°C and therefore considered a specific amplification product. The PCR fragment was blunt-ended and inserted into pUC18 previously digested by HindII. After transformation of E. coli XL1-Blue, the recombinant plasmid, named pClone5, was purified, and the insert was sequenced. The DNA sequence corresponded to the amino acid sequences determined for peptides S1441 and S1443 (not shown), indicating that the PCR fragment contains part of the gene coding for HBHA. To clone the entire HBHA structural gene, the PCR product was isolated from pClone5 by digestion with BamHI and HindIII, purified by electroelution from a polyacrylamide gel, labeled with digoxigenin, and used as a probe for Southern blot analyses of chromosomal BCG DNA cut with various restriction enzymes. Except for SmaI, each restriction enzyme yielded a single hybridizing band (Fig. 1), suggesting that the HBHA structural gene is present in a single copy in the BCG chromosome. As expected, two bands were obtained after digestion with SmaI, because the pClone5 insert contains a SmaI site. SphI fragments from 2.3 to 2.7 kb, which were long enough to potentially contain the entire HBHA gene, were purified by electroelution and inserted into pUC18 cut with SphI. After transformation of E. coli XL1-Blue, the recombinant colonies were analyzed by colony blot hybridization using the digoxigenin-labeled 150 bp probe of pClone5. Among the 300 colonies analyzed, one hybridized strongly with the probe. Restriction analysis of this clone revealed that its plasmid, named pHBHA, contained a 2.5-kb SphI insert. Location of the HBHA gene within this fragment was confirmed by restriction and Southern blot analyses, as well as by DNA sequencing.

View this table:

Table 2

Amino acid sequences of HBHA peptides

Figure 1

Southern blot analysis of the HBHA-coding gene. Total DNA was extracted from M. bovis BCG, digested with BamHI (lane 1), EcoRI (lane 2), PstI (lane 3), SmaI (lane 4), AccI (lane 5), NcoI (lane 6), NotI (lane 7), SacI (lane 8), or SphI (lane 9) and subjected to agarose-gel electrophoresis and transfer onto a nylon membrane. The membrane then was probed with the approximately 150-bp BamHI–HindIII fragment of pClone5. The sizes of the markers are shown on the right.

Analysis of the HBHA Structural Gene.

The nucleotide sequence of the right side of the 2.5-kb SphI insert of pHBHA is shown in Fig. 2. An ORF was found between nucleotides 331 and 927 with a coding potential of 199 amino acids. The deduced amino acid sequence of the first 16 codons following the first in-frame ATG codon was found to be identical to the determined amino-terminal sequence of purified HBHA (11). In addition, all internal peptide sequences of HBHA shown in Table 2 were found in the deduced amino acid sequence shown in Fig. 2, allowing us to conclude that this ORF contains the HBHA-coding sequence.

Figure 2

Sequence of the HBHA-coding gene. The nucleotide sequence of the HBHA-coding gene is indicated by lowercase letters. The bold letters show the putative ribosomal-binding site, and the letters in italics indicate the SphI site. The numbers refer to the numbers of the nucleotides. The capital letters represent the amino acid sequence in the single letter code. ∗ denotes the stop of the amino acid sequence. The amino acids that were determined by peptide sequencing are underlined. The boxed sequences correspond to the Lys/Pro-rich repeats.

Codon 331–333 of the sequence is most likely the initiation codon, because no other in-frame ATG or GTG was found further upstream following the first in-frame stop codon at position 310–312. Moreover, a putative ribosome binding site (AGGAA) was found 6–10 nt upstream of this ATG. Because the first amino acid of purified HBHA is the first residue following the initiation methionine, the protein does not appear to contain a signal sequence, although it is found surface-associated and secreted in mycobacterial cultures (11). This observation suggests that HBHA is secreted in a sec-independent manner.

The predicted mature protein contains no methionine, no histidine, no cysteine, and no tryptophan. Interestingly, HBHA contains lysine-rich repeats in its carboxyl-terminal region. Two different strictly repeated motifs were identified (boxed in Fig. 2). The KKAAPA motif is directly repeated three times between residues 160 and 177, whereas the KKAAAKK motif is repeated two times between amino acids 178 and 194. An APA sequence separates the two repeats. The calculated molecular weight of HBHA is 21,331, substantially lower than its apparent molecular weight of approximately 28,000 as determined by SDS/PAGE. This discrepancy could be the result of an aberrant electrophoretic mobility of HBHA because of the K-A-P-rich carboxyl-terminal domain and/or to a posttranslational modification of the protein.

Cloning and Sequence of the M. tuberculosis HBHA Structural Gene.

Because HBHA also is produced by M. tuberculosis (11), we used two synthetic oligonucleotides (oligonucleotides HBHA Seq6 and HBHA Seq7, Table 1) corresponding to the upstream and downstream regions of the BCG HBHA structural gene to amplify, by PCR, a 0.8-kb DNA fragment of the M. tuberculosis H37Rv chromosome. The amplified DNA fragment was ligated into pUC18 previously linearized by HindII restriction. Sequence analysis of the cloned PCR fragment demonstrated that the M. tuberculosis HBHA gene sequence is the same as the sequence of the BCG HBHA gene.

Production of HBHA in E. coli.

The expression vector pKK388–1 was used to produce HBHA in E. coli. The 705-bp NcoI–KpnI fragment of pHBHA was inserted into pKK388–1 that had been previously restricted by NcoI and KpnI. The recombinant plasmid, named pKK-HBHA, then was introduced into E. coli XL1-Blue. The synthesis of recombinant HBHA was induced by the addition of IPTG and detected by SDS/PAGE and immunoblot analysis of E. coli whole-cell lysates (Fig. 3). E. coli XL1-Blue (pKK-HBHA) produced a polypeptide of approximately 27 kDa (Fig. 3, Left, lanes B and D), which was not found in extracts of E. coli XL1-Blue(pKK388–1). Although the apparent molecular weight of this recombinant protein is still higher than the calculated molecular weight, it is lower than that of HBHA purified from BCG or M. tuberculosis H37Ra (compare lanes E to lanes D in Fig. 3). This observation suggests that the native mycobacterial HBHA is posttranslationally modified.

Figure 3

Production of recombinant HBHA in E. coli. E. coli XL1-Blue containing pKK388–1 (lanes A and C) or containing pKK-HBHA (lanes B and D) were incubated in the presence of IPTG (lanes C and D). Cell extracts were prepared and analyzed by SDS/PAGE and Coomassie blue staining (Left) or by immunoblot analysis using only secondary conjugated antibodies (second panel), anti-HBHA polyclonal antibodies (third panel), or mABs 3921E4 and 4057D2 (fourth and fifth, panels, respectively). Lanes E contain authentic HBHA purified from BCG culture supernatants. The sizes of the M_r markers given in kDa are shown on the left.

To confirm that the 27-kDa protein in E. coli XL1-Blue(pKK-HBHA) extracts corresponds to the recombinant HBHA, immunoblot analyses were carried out by using murine polyclonal anti-HBHA antibodies, as well as mABs 3921E4 and 4057D2 reactive with HBHA (30). The polyclonal antibodies and mAB 3921E4 recognized purified BCG HBHA (Fig. 3, lanes E) and the recombinant polypeptide produced by E. coli XL1-Blue(pKK-HBHA) (Fig. 3, lanes D). No immunoreactivity was detected in lysates of IPTG-induced E. coli XL1-Blue(pKK388–1), confirming that the 27-kDa protein corresponds to the recombinant HBHA. Surprisingly, mAB 4057D2 did not recognize the recombinant form of HBHA, indicating that its epitope is not present in the recombinant protein (Fig. 3, Right). Under the same electrophoresis and immunoblotting conditions mAB 4057D2 did recognize HBHA purified from mycobacteria, which suggests that its epitope may depend on the posttranslational modification of native HBHA.

Evidence for Glycosylation of HBHA.

HBHA was purified from BCG culture supernatants and analyzed for potential monosaccharide composition by derivatization using trimethylsilane followed by combined GC/mass spectrophotometry analysis. The results of the glycosyl composition analysis indicate that glucose is the major component (41.6%), with lesser amounts of xylose (17%), mannose (10.2%), arabinose (8.8%), and galactose (6.2%). An unidentified component with a GC retention time of 29.02 min had a mass spectrum that was similar, but not identical with 2-keto-3-deoxy-d-manno-octulosonic acid.

Based on an estimate of the protein concentration of the purified HBHA sample, the total amount of carbohydrate represents 2.8% of the mass of HBHA, which is consistent with the observed difference in electrophoretic mobility between the authentic HBHA and the recombinant protein.

Susceptibility of Recombinant HBHA to Proteolytic Degradation.

The IPTG-induced production of recombinant HBHA did not lead to the formation of inclusion bodies in E. coli, because most of the recombinant protein was recovered in the soluble fraction after sonication and subsequent clarification of the lysate by centrifugation (data not shown). However, soluble recombinant HBHA was rapidly degraded. During incubation of the lysate at room temperature, recombinant HBHA rapidly degraded into a 19-kDa polypeptide that was resistant to further degradation. This polypeptide was no longer recognized by mAB 3921E4, indicating that the epitope for mAB 3921E4 was lost after this cleavage (Fig. 4). After 2 hr of incubation at room temperature, the 27-kDa protein was completely cleaved into the 19-kDa form and was no longer reactive with mAB 3921E4. Because the carboxyl-terminal region of HBHA is rich in basic amino acids containing potential cleavage sites for serine endopeptidases, AEBSF, a strong, nontoxic inhibitor of serine proteases, was added to the E. coli lysate at a final concentration of 1 mM. Under these conditions, recombinant HBHA remained stable even after 18 hr of incubation at room temperature (Fig. 4, Right), suggesting that the recombinant HBHA was cleaved by the action of a serine protease. When the purified native HBHA was mixed with an equal volume of E. coli lysate, it did not undergo the cleavage observed with recombinant HBHA (data not shown), suggesting that the glycosylation of native HBHA protects the protein against proteolytic cleavage.

Figure 4

Instability of recombinant HBHA. After induction with IPTG, E. coli (pKK-HBHA) cell extracts were incubated at room temperature either in the presence of AEBSF or in its absence. At the indicated time points the extracts then were analyzed by SDS/PAGE and Coomassie blue staining (Left) or by immunoblotting using mAB 3921E4 (Right). The sizes of the M_r markers given in kDa are shown on the left.

Activities of Recombinant HBHA.

To investigate whether recombinant HBHA is able to bind to sulfated carbohydrates, a lysate of IPTG-induced E. coli XL1-Blue(pKK-HBHA) was chromatographed on heparin-Sepharose at 4°C in the presence of 1 mM AEBSF. Recombinant HBHA eluted at approximately 350 mM NaCl (data not shown). This chromatographic behavior was identical to that of native HBHA (11), indicating that both HBHA forms interact similarly with sulfated polysaccharides.

When AEBSF was omitted during chromatography, HBHA was recovered as a 19-kDa protein, which no longer bound to heparin. This finding suggests that the cleaved region of HBHA is involved in binding of HBHA to heparin. To investigate which region of HBHA is involved in heparin-binding, heparin-Sepharose purified recombinant HBHA was incubated at 37°C for 2 hr. Three distinct peptides were detected upon SDS/PAGE and Coomassie blue staining, the 27-kDa protein, as well as two peptides with apparent molecular weights of approximately 26,000 and 25,000. Also, after 6 hr of incubation, the 19-kDa form became apparent (not shown). Partial amino acid sequencing of these peptides revealed that they all contained the amino-terminal sequence of HBHA, indicating that the degradation occurred at the carboxy-terminus of the protein. Moreover, immunoblot analysis showed that the 25-kDa and 19-kDa HBHA species were no longer detected by mAB 3921E4, indicating that its epitope is located in the carboxyl end of the protein. When these recombinant proteins were applied onto a heparin-Sepharose column, the 19-kDa form did not bind, whereas all other fragments of HBHA bound to heparin. After gradient elution, the smaller forms (25 and 26 kDa) eluted before the 27-kDa form (Fig. 5), indicating that heparin binding also requires the carboxyl-terminal domain of HBHA, and that progressive truncations from the C-terminal end diminish the affinity for heparin.

Figure 5

Elution of recombinant HBHA proteins from heparin-Sepharose. Recombinant HBHA was applied onto a heparin-Sepharose column, and the bound material was eluted by a linear 0– 500 mM NaCl gradient. The eluted fractions were analyzed by SDS/PAGE and Coomassie blue staining (Upper) and by immunoblotting using mAB 3921E4 (Lower). The three forms of recombinant HBHA (approximately 27 kDa, 26 kDa, and 25 kDa) are indicated by A, B, and C, respectively. The fractions analyzed go from low-salt (Left) to high-salt elution (Right). Note that the larger M_r species elute at higher salt concentrations and that the 25-kDa form is not recognized by mAB 3921E4.

As shown previously (11), purified native HBHA agglutinates rabbit erythrocytes, whereas heparin-Sepharose-purified, full-length recombinant HBHA failed to induce hemagglutination, suggesting that this activity depends on the glycosylation of HBHA.

DISCUSSION

In this study we describe the molecular characterization of a mycobacterial adhesin. This protein recently was identified as a surface-exposed HBHA involved in the adherence of M. tuberculosis to epithelial cells (11). The M_r deduced from the amino acid sequence was found to be smaller than the apparent M_r estimated by SDS/PAGE. This difference could be attributed to the Pro/Lys-rich C-terminal region of HBHA. However, in addition, SDS/PAGE analyses indicated that the apparent M_r of recombinant HBHA was approximately 1 kDa lower than that of native HBHA. This difference may be related to a posttranslational modification of the protein in mycobacteria, because GC/mass spectrophotometry analysis revealed that native HBHA contains ca. 2.8% carbohydrate. Combined GC/mass spectrophotometry analysis indicated that the carbohydrate moiety of HBHA was composed of glucose, some xylose, mannose, arabinose, galactose, and an unidentified component. It remains to be proven that an oligosaccharide is covalently linked to the protein core of HBHA. Interestingly, among the two anti-HBHA mABs one (4057D2) recognized native HBHA and not the recombinant form, suggesting that the glycosylation contributes to the epitope of this mAB. This finding may aid in the identification of functional sites on HBHA because the mABs have been shown to inhibit hemagglutination and mycobacterial attachment to eukaryotic cells (11).

Glycosylation is common among eukaryotic membrane and secretory proteins, but much less so in bacteria. Although glycoproteins have been known for some time to occur in archaebacteria, their existence in eubacteria has only recently been established. Some of the eubacterial glycoproteins constitute virulence factors, especially adhesins, such as the fiber-forming pilin of Neisseria gonorrhoeae (33). In contrast to most bacteria, mycobacteria produce a number of different glycoproteins, and our evidence suggests that HBHA is an additional member of this group. In M. tuberculosis, several antigens have been identified as glycoproteins that range in size from 19 kDa (34) to 55 kDa (35). Some of these antigens also have been detected in M. bovis (36). So far, two of the glycoproteins also are known to contain lipid moieties at their amino terminus (34, 35). Although detailed chemical analyses have been reported for some of these glycoproteins (37), their function remains unknown, with the exception of the 38-kDa lipoprotein, which is likely involved in phosphate uptake (38). A recent study indicated that the glycosylation of the M. tuberculosis 19-kDa lipoprotein alters proteolytic cleavage of the molecule by conferring resistance to certain proteases (39).

Recombinant HBHA was found to be sensitive to proteolytic cleavage, whereas HBHA purified from BCG was not easily degraded, even when incubated in the presence of a crude E. coli extract. The proteolytic degradation of recombinant HBHA occurred primarily in the C-terminal region. Similar to the recent study on the role of glycosylation of the 19-kDa mycobacterial lipoprotein (39), glycosylation also appears to protect HBHA from proteolytic degradation. This finding suggests that the carbohydrate moiety of HBHA may be located within the C domain of the protein. Alternatively, glycosylation could occur elsewhere in the protein and induce a folding that confers resistance to proteolytic degradation. In eukaryotes, for example, there is evidence that glycosylation plays a role in protein folding (40).

In addition to its role in antigenicity and in protection against proteolysis, the glycosylation also appeared to be important for HBHA-mediated hemagglutination. Although the physiological significance of hemagglutination is not known, many bacterial adhesins that mediate attachment of the microorganisms to host cells express hemagglutination activity. It may be that the glycosylation of HBHA plays a role in promoting adherence of the mycobacteria, similar to what has been proposed for the role of glycosylation of the N. meningitidis pilin (41). However, a definitive answer to this question awaits careful comparisons of the binding activities of wild-type mycobacteria with those of isogenic mutant strains producing HBHA that is not glycosylated.

Because recombinant HBHA binds to heparin in a similar fashion as native HBHA, the loss of glycosylation appears not to influence the binding to sulfated carbohydrates. Amino acid sequence analysis revealed that the C-terminal region of HBHA contains Pro/Lys-rich repeats. One of them (KKAAPA) is directly repeated three times, and a second one (KKAAAKK) is repeated two times separated by an APA sequence. Progressive removal of these repeats in the recombinant protein decreased the binding to heparin-Sepharose. The removal of all five repeats totally abolished heparin binding, indicating that they play an essential role in the interaction with sulfated carbohydrates. Lysines are known to play a key role in the binding activities of proteins that specifically interact with sulfated sugars (42). Because lysines are also prone to proteolytic attack by serine proteases, the protection against proteolysis by glycosylation of HBHA may be crucial to maintaining the biological activities of HBHA as an adhesin.

Although amino acid sequence analysis revealed the absence of a signal peptide, cell-fractionation experiments and immuno-electron microscopy analyses clearly established that HBHA is a surface-associated as well as a secreted protein in M. tuberculosis and M. bovis (11). Instead of a signal peptide sequence, the first amino acid of the mature form of the protein is immediately preceded by the initiation methionine. This observation indicates that HBHA is secreted in a signal-peptide independent manner. Because glycosylation has been shown to play a role in protein export in other systems (43), it is conceivable that the glycosylation of HBHA also is involved in the secretion of this protein. Production of a nonglycosylated mutant HBHA in mycobacteria may clarify this hypothesis. It is also possible that the secretion of HBHA requires the coordinated production of accessory proteins. In many cases, the genes encoding the accessory proteins are located in the vicinity of the structural gene (44). The cloning and sequence analysis of the sequences upstream and downstream of the HBHA structural gene hopefully will provide some evidence for the existence of possible genes.

Acknowledgments

We thank the Carbohydrate Research Center at the University of Georgia for the determination of the carbohydrate content of HBHA, and D. Rouse and S. Morris for the 4057D2 and 3921E4 hybridomas. The work was supported, in part, by Institut Pasteur de Lille, Institut National de la Santé et de la Recherche Médicale, Région Nord-Pas de Calais, Caisse Nationale d’Assurances Maladies des Travailleurs Salariés, and Ministère de l’Education Nationale, de l’Enseignement Supérieur, de la Recherche et de l’Insertion Professionnelle.

Footnotes

↵‡ Present address: Astra-Draco, AB, Department of Bioanalytical Chemistry, P.O. Box 34, S-221 00 Lund, Sweden.
↵¶ To whom reprint requests should be addressed: e-mail: Camille.Locht{at}pasteur-lille.fr.
Data deposition: The sequence reported in this paper has been deposited in the GenBank database (accession no. AF07390).

ABBREVIATIONS

HBHA,: heparin-binding hemagglutinin;
BCG,: bacillus Calmette–Guérin;
IPTG,: isopropyl β-d-thiogalactoside;
AEBSF,: 4-(2-aminoethyl)-benzenesulfonyl fluoride

Received August 11, 1997.
Accepted June 10, 1998.

View Abstract

References

↵
1. Raviglione M C,
2. Snider D E,
3. Kochi A
(1995) J Am Med Assoc 273:220–226, pmid:7807661.
OpenUrl Abstract/FREE Full Text
↵
1. Horsburgh C R
(1991) N Engl J Med 324:1332–1338, pmid:2017230.
OpenUrl PubMed
↵
1. Shepard C C
(1957) J Exp Med 105:39–48, pmid:13385405.
OpenUrl Abstract
↵
1. Mapothar M E,
2. Sanger J G
(1984) Infect Immun 45:67–73, pmid:6329959.
OpenUrl Abstract/FREE Full Text
1. McDonough K A,
2. Kress Y
(1995) Infect Immun 63:4802–4811, pmid:7591139.
OpenUrl Abstract/FREE Full Text
1. Bermudez L E,
2. Goodman J
(1996) Infect Immun 64:1400–1406, pmid:8606107.
OpenUrl Abstract/FREE Full Text
↵
1. Ratliff T L,
2. McCarthy R,
3. Telle W B,
4. Brown E J
(1993) Infect Immun 61:1889–1894, pmid:8478078.
OpenUrl Abstract/FREE Full Text
↵
1. Schlesinger L S,
2. Bellinger-Kawahara C G,
3. Payne N R,
4. Horwitz M A
(1990) J Immunol 144:2771–2780, pmid:2108212.
OpenUrl Abstract
1. Schlesinger L S,
2. Horwitz M A
(1990) J Clin Invest 85:1304–1314, pmid:2138634.
OpenUrl PubMed
↵
1. Hirsch C S,
2. Ellner J J,
3. Russell D G,
4. Rich E A
(1994) J Immunol 152:743–753, pmid:8283049.
OpenUrl Abstract
↵
1. Menozzi F D,
2. Rouse J H,
3. Alavi M,
4. Laude-Sharp M,
5. Muller J,
6. Bischoff R,
7. Brennan M J,
8. Locht C
(1996) J Exp Med 184:993–1001, pmid:9064359.
OpenUrl Abstract/FREE Full Text
↵
1. Menozzi F D,
2. Mutombo R,
3. Renauld G,
4. Gantiez C,
5. Hannah J H,
6. Leininger E,
7. Brennan M J,
8. Locht C
(1994) Infect Immun 62:769–778, pmid:8112848.
OpenUrl Abstract/FREE Full Text
1. Hannah J H,
2. Menozzi F D,
3. Renauld G,
4. Locht C,
5. Brennan M J
(1994) Infect Immun 62:5010–5019, pmid:7927782.
OpenUrl Abstract/FREE Full Text
1. Krivan H C,
2. Olson L D,
3. Barile M F,
4. Ginsburg V,
5. Roberts D
(1989) J Biol Chem 264:9283–9288, pmid:2470753.
OpenUrl Abstract/FREE Full Text
1. Isaacs R D
(1994) J Clin Invest 93:809–819, pmid:8113413.
OpenUrl PubMed
↵
1. Van Putten J P M,
2. Paul S M
(1995) EMBO J 14:2144–2154, pmid:7774572.
OpenUrl PubMed
↵
1. Nahmias A J,
2. Kibrick S
(1964) J Bacteriol 87:1060–1066, pmid:4289440.
OpenUrl Abstract/FREE Full Text
1. Compton T,
2. Nowlin D M,
3. Cooper N R
(1993) Virology 193:834–841, pmid:8384757.
OpenUrl CrossRef PubMed
↵
1. Shieh M-T,
2. Spear P G
(1994) J Virol 68:1224–1228, pmid:8289356.
OpenUrl Abstract/FREE Full Text
↵
1. Ortega-Barria E,
2. Pereira E A
(1991) Cell 67:411–421, pmid:1655283.
OpenUrl CrossRef PubMed
1. Frevert U,
2. Sinnis P,
3. Cerami C,
4. Shreffler W,
5. Takacs B,
6. Nussenzweig V
(1993) J Exp Med 177:1287–1298, pmid:8478608.
OpenUrl Abstract/FREE Full Text
↵
1. Love D C,
2. Esko J D,
3. Mosser D M
(1993) J Cell Biol 123:759–766, pmid:8227137.
OpenUrl Abstract/FREE Full Text
↵
1. Sambrook J,
2. Fritsch E F,
3. Maniatis T
(1989) Molecular Cloning: A Laboratory Manual (Cold Spring Harbor Lab. Press, Plainview, NY), 2nd Ed..
↵
1. Sanger F,
2. Nicklen S,
3. Coulson A R
(1977) Proc Natl Acad Sci USA 74:5463–5467, pmid:271968.
OpenUrl Abstract/FREE Full Text
↵
1. Baulard A,
2. Kremer L,
3. Locht C
(1996) J Bacteriol 178:3091–3098, pmid:8655485.
OpenUrl Abstract/FREE Full Text
↵
1. Laemmli U K
(1970) Nature (London) 227:680–685, pmid:5432063.
OpenUrl CrossRef PubMed
↵
1. York W S,
2. Darvill A G,
3. McNeil M,
4. Stevenson T T,
5. Albersheim P
(1985) Methods Enzymol 118:3–40.
OpenUrl
↵
1. Merkle R K,
2. Poppe I
(1994) Methods Enzymol 230:1–15, pmid:8139491.
OpenUrl CrossRef PubMed
↵
1. Towbin H,
2. Staehlin T,
3. Gordon J
(1979) Proc Natl Acad Sci USA 76:4350–4354, pmid:388439.
OpenUrl Abstract/FREE Full Text
↵
1. Rouse D A,
2. Morris S L,
3. Karpas A B,
4. Mackall J C,
5. Probst P G,
6. Chaparas S D
(1991) Infect Immun 59:2595–2600, pmid:1713196.
OpenUrl Abstract/FREE Full Text
↵
1. Bradford M M
(1976) Anal Biochem 72:248–254, pmid:942051.
OpenUrl CrossRef PubMed
↵
1. Sneath P H A,
2. Mair N S,
3. Sharp M E,
4. Holt J G
1. Wayne L G,
2. Kubica G P
(1986) in Bergey’s Manual of Systematic Bacteriology, eds Sneath P H A, Mair N S, Sharp M E, Holt J G(Williams & Wilkins, Baltimore), pp 1436–1457.
↵
1. Parge H E,
2. Forest K T,
3. Hickey M J,
4. Christensen D A,
5. Getzoff E D,
6. Tainer J A
(1995) Nature (London) 378:32–38, pmid:7477282.
OpenUrl CrossRef PubMed
↵
1. Garbe T,
2. Harris D,
3. Vordermeier M,
4. Lathigra R,
5. Ivanyi J,
6. Young D
(1993) Infect Immun 61:260–267, pmid:8418047.
OpenUrl Abstract/FREE Full Text
↵
1. Espitia C,
2. Mancilla R
(1989) Clin Exp Immunol 77:378–383, pmid:2478323.
OpenUrl PubMed
↵
1. Fifis T,
2. Costopoulos C,
3. Radford A J,
4. Bacic A,
5. Wood P R
(1991) Infect Immun 59:800–807, pmid:1900061.
OpenUrl Abstract/FREE Full Text
↵
1. Dobos K M,
2. Swiderek K,
3. Khoo K-H,
4. Brennan P J,
5. Belisle J T
(1995) Infect Immun 63:2846–2853, pmid:7622204.
OpenUrl Abstract/FREE Full Text
↵
1. Andersen A B,
2. Ljungqvist L,
3. Olsen M
(1990) J Gen Microbiol 136:477–480, pmid:2118164.
OpenUrl Abstract/FREE Full Text
↵
1. Herrmann J L,
2. O’Gaora P,
3. Gallagher A,
4. Thola J E R,
5. Young D B
(1996) EMBO J 15:3547–3554, pmid:8670858.
OpenUrl PubMed
↵
1. Ruddon R W,
2. Bedows E
(1997) J Biol Chem 272:3125–3128, pmid:9081984.
OpenUrl FREE Full Text
↵
1. Virji M,
2. Saunders J R,
3. Sims G,
4. Makepeace K,
5. Maskell D,
6. Ferguson D J P
(1993) Mol Microbiol 10:1013–1028, pmid:7934852.
OpenUrl PubMed
↵
1. Cardin A D,
2. Weintraub H J R
(1989) Arteriosclerosis 9:21–32, pmid:2463827.
OpenUrl Abstract/FREE Full Text
↵
1. Kubicek C P
(1982) Adv Biochem Eng Biotechnol 45:1–27.
OpenUrl
↵
1. Pugsley A P
(1993) Microbiol Rev 57:50–108, pmid:8096622.
OpenUrl Abstract/FREE Full Text

Article Alerts

Email Article

Citation Tools

Request Permissions

Proceedings of the National Academy of Sciences: 95 (21)

Table of Contents

Submit

[1] ↵
Raviglione M C,
Snider D E,
Kochi A
(1995) J Am Med Assoc 273:220–226, pmid:7807661.
OpenUrl Abstract/FREE Full Text

[2] Raviglione M C,

[3] Snider D E,

[4] Kochi A

[5] ↵
Horsburgh C R
(1991) N Engl J Med 324:1332–1338, pmid:2017230.
OpenUrl PubMed

[6] Horsburgh C R

[7] ↵
Shepard C C
(1957) J Exp Med 105:39–48, pmid:13385405.
OpenUrl Abstract

[8] Shepard C C

[9] ↵
Mapothar M E,
Sanger J G
(1984) Infect Immun 45:67–73, pmid:6329959.
OpenUrl Abstract/FREE Full Text

[10] Mapothar M E,

[11] Sanger J G

[12] McDonough K A,
Kress Y
(1995) Infect Immun 63:4802–4811, pmid:7591139.
OpenUrl Abstract/FREE Full Text

[13] McDonough K A,

[14] Kress Y

[15] Bermudez L E,
Goodman J
(1996) Infect Immun 64:1400–1406, pmid:8606107.
OpenUrl Abstract/FREE Full Text

[16] Bermudez L E,

[17] Goodman J

[18] ↵
Ratliff T L,
McCarthy R,
Telle W B,
Brown E J
(1993) Infect Immun 61:1889–1894, pmid:8478078.
OpenUrl Abstract/FREE Full Text

[19] Ratliff T L,

[20] McCarthy R,

[21] Telle W B,

[22] Brown E J

[23] ↵
Schlesinger L S,
Bellinger-Kawahara C G,
Payne N R,
Horwitz M A
(1990) J Immunol 144:2771–2780, pmid:2108212.
OpenUrl Abstract

[24] Schlesinger L S,

[25] Bellinger-Kawahara C G,

[26] Payne N R,

[27] Horwitz M A

[28] Schlesinger L S,
Horwitz M A
(1990) J Clin Invest 85:1304–1314, pmid:2138634.
OpenUrl PubMed

[29] Schlesinger L S,

[30] Horwitz M A

[31] ↵
Hirsch C S,
Ellner J J,
Russell D G,
Rich E A
(1994) J Immunol 152:743–753, pmid:8283049.
OpenUrl Abstract

[32] Hirsch C S,

[33] Ellner J J,

[34] Russell D G,

[35] Rich E A

[36] ↵
Menozzi F D,
Rouse J H,
Alavi M,
Laude-Sharp M,
Muller J,
Bischoff R,
Brennan M J,
Locht C
(1996) J Exp Med 184:993–1001, pmid:9064359.
OpenUrl Abstract/FREE Full Text

[37] Menozzi F D,

[38] Rouse J H,

[39] Alavi M,

[40] Laude-Sharp M,

[41] Muller J,

[42] Bischoff R,

[43] Brennan M J,

[44] Locht C

[45] ↵
Menozzi F D,
Mutombo R,
Renauld G,
Gantiez C,
Hannah J H,
Leininger E,
Brennan M J,
Locht C
(1994) Infect Immun 62:769–778, pmid:8112848.
OpenUrl Abstract/FREE Full Text

[46] Menozzi F D,

[47] Mutombo R,

[48] Renauld G,

[49] Gantiez C,

[50] Hannah J H,

[51] Leininger E,

[52] Brennan M J,

[53] Locht C

[54] Hannah J H,
Menozzi F D,
Renauld G,
Locht C,
Brennan M J
(1994) Infect Immun 62:5010–5019, pmid:7927782.
OpenUrl Abstract/FREE Full Text

[55] Hannah J H,

[56] Menozzi F D,

[57] Renauld G,

[58] Locht C,

[59] Brennan M J

[60] Krivan H C,
Olson L D,
Barile M F,
Ginsburg V,
Roberts D
(1989) J Biol Chem 264:9283–9288, pmid:2470753.
OpenUrl Abstract/FREE Full Text

[61] Krivan H C,

[62] Olson L D,

[63] Barile M F,

[64] Ginsburg V,

[65] Roberts D

[66] Isaacs R D
(1994) J Clin Invest 93:809–819, pmid:8113413.
OpenUrl PubMed

[67] Isaacs R D

[68] ↵
Van Putten J P M,
Paul S M
(1995) EMBO J 14:2144–2154, pmid:7774572.
OpenUrl PubMed

[69] Van Putten J P M,

[70] Paul S M

[71] ↵
Nahmias A J,
Kibrick S
(1964) J Bacteriol 87:1060–1066, pmid:4289440.
OpenUrl Abstract/FREE Full Text

[72] Nahmias A J,

[73] Kibrick S

[74] Compton T,
Nowlin D M,
Cooper N R
(1993) Virology 193:834–841, pmid:8384757.
OpenUrl CrossRef PubMed

[75] Compton T,

[76] Nowlin D M,

[77] Cooper N R

[78] ↵
Shieh M-T,
Spear P G
(1994) J Virol 68:1224–1228, pmid:8289356.
OpenUrl Abstract/FREE Full Text

[79] Shieh M-T,

[80] Spear P G

[81] ↵
Ortega-Barria E,
Pereira E A
(1991) Cell 67:411–421, pmid:1655283.
OpenUrl CrossRef PubMed

[82] Ortega-Barria E,

[83] Pereira E A

[84] Frevert U,
Sinnis P,
Cerami C,
Shreffler W,
Takacs B,
Nussenzweig V
(1993) J Exp Med 177:1287–1298, pmid:8478608.
OpenUrl Abstract/FREE Full Text

[85] Frevert U,

[86] Sinnis P,

[87] Cerami C,

[88] Shreffler W,

[89] Takacs B,

[90] Nussenzweig V

[91] ↵
Love D C,
Esko J D,
Mosser D M
(1993) J Cell Biol 123:759–766, pmid:8227137.
OpenUrl Abstract/FREE Full Text

[92] Love D C,

[93] Esko J D,

[94] Mosser D M

[95] ↵
Sambrook J,
Fritsch E F,
Maniatis T
(1989) Molecular Cloning: A Laboratory Manual (Cold Spring Harbor Lab. Press, Plainview, NY), 2nd Ed..

[96] Sambrook J,

[97] Fritsch E F,

[98] Maniatis T

[99] ↵
Sanger F,
Nicklen S,
Coulson A R
(1977) Proc Natl Acad Sci USA 74:5463–5467, pmid:271968.
OpenUrl Abstract/FREE Full Text

[100] Sanger F,

[101] Nicklen S,

[102] Coulson A R

[103] ↵
Baulard A,
Kremer L,
Locht C
(1996) J Bacteriol 178:3091–3098, pmid:8655485.
OpenUrl Abstract/FREE Full Text

[104] Baulard A,

[105] Kremer L,

[106] Locht C

[107] ↵
Laemmli U K
(1970) Nature (London) 227:680–685, pmid:5432063.
OpenUrl CrossRef PubMed

[108] Laemmli U K

[109] ↵
York W S,
Darvill A G,
McNeil M,
Stevenson T T,
Albersheim P
(1985) Methods Enzymol 118:3–40.
OpenUrl

[110] York W S,

[111] Darvill A G,

[112] McNeil M,

[113] Stevenson T T,

[114] Albersheim P

[115] ↵
Merkle R K,
Poppe I
(1994) Methods Enzymol 230:1–15, pmid:8139491.
OpenUrl CrossRef PubMed

[116] Merkle R K,

[117] Poppe I

[118] ↵
Towbin H,
Staehlin T,
Gordon J
(1979) Proc Natl Acad Sci USA 76:4350–4354, pmid:388439.
OpenUrl Abstract/FREE Full Text

[119] Towbin H,

[120] Staehlin T,

[121] Gordon J

[122] ↵
Rouse D A,
Morris S L,
Karpas A B,
Mackall J C,
Probst P G,
Chaparas S D
(1991) Infect Immun 59:2595–2600, pmid:1713196.
OpenUrl Abstract/FREE Full Text

[123] Rouse D A,

[124] Morris S L,

[125] Karpas A B,

[126] Mackall J C,

[127] Probst P G,

[128] Chaparas S D

[129] ↵
Bradford M M
(1976) Anal Biochem 72:248–254, pmid:942051.
OpenUrl CrossRef PubMed

[130] Bradford M M

[131] ↵
Sneath P H A,
Mair N S,
Sharp M E,
Holt J G
Wayne L G,
Kubica G P
(1986) in Bergey’s Manual of Systematic Bacteriology, eds Sneath P H A, Mair N S, Sharp M E, Holt J G(Williams & Wilkins, Baltimore), pp 1436–1457.

[132] Sneath P H A,

[133] Mair N S,

[134] Sharp M E,

[135] Holt J G

[136] Wayne L G,

[137] Kubica G P

[138] ↵
Parge H E,
Forest K T,
Hickey M J,
Christensen D A,
Getzoff E D,
Tainer J A
(1995) Nature (London) 378:32–38, pmid:7477282.
OpenUrl CrossRef PubMed

[139] Parge H E,

[140] Forest K T,

[141] Hickey M J,

[142] Christensen D A,

[143] Getzoff E D,

[144] Tainer J A

[145] ↵
Garbe T,
Harris D,
Vordermeier M,
Lathigra R,
Ivanyi J,
Young D
(1993) Infect Immun 61:260–267, pmid:8418047.
OpenUrl Abstract/FREE Full Text

[146] Garbe T,

[147] Harris D,

[148] Vordermeier M,

[149] Lathigra R,

[150] Ivanyi J,

[151] Young D

[152] ↵
Espitia C,
Mancilla R
(1989) Clin Exp Immunol 77:378–383, pmid:2478323.
OpenUrl PubMed

[153] Espitia C,

[154] Mancilla R

[155] ↵
Fifis T,
Costopoulos C,
Radford A J,
Bacic A,
Wood P R
(1991) Infect Immun 59:800–807, pmid:1900061.
OpenUrl Abstract/FREE Full Text

[156] Fifis T,

[157] Costopoulos C,

[158] Radford A J,

[159] Bacic A,

[160] Wood P R

[161] ↵
Dobos K M,
Swiderek K,
Khoo K-H,
Brennan P J,
Belisle J T
(1995) Infect Immun 63:2846–2853, pmid:7622204.
OpenUrl Abstract/FREE Full Text

[162] Dobos K M,

[163] Swiderek K,

[164] Khoo K-H,

[165] Brennan P J,

[166] Belisle J T

[167] ↵
Andersen A B,
Ljungqvist L,
Olsen M
(1990) J Gen Microbiol 136:477–480, pmid:2118164.
OpenUrl Abstract/FREE Full Text

[168] Andersen A B,

[169] Ljungqvist L,

[170] Olsen M

[171] ↵
Herrmann J L,
O’Gaora P,
Gallagher A,
Thola J E R,
Young D B
(1996) EMBO J 15:3547–3554, pmid:8670858.
OpenUrl PubMed

[172] Herrmann J L,

[173] O’Gaora P,

[174] Gallagher A,

[175] Thola J E R,

[176] Young D B

[177] ↵
Ruddon R W,
Bedows E
(1997) J Biol Chem 272:3125–3128, pmid:9081984.
OpenUrl FREE Full Text

[178] Ruddon R W,

[179] Bedows E

[180] ↵
Virji M,
Saunders J R,
Sims G,
Makepeace K,
Maskell D,
Ferguson D J P
(1993) Mol Microbiol 10:1013–1028, pmid:7934852.
OpenUrl PubMed

[181] Virji M,

[182] Saunders J R,

[183] Sims G,

[184] Makepeace K,

[185] Maskell D,

[186] Ferguson D J P

[187] ↵
Cardin A D,
Weintraub H J R
(1989) Arteriosclerosis 9:21–32, pmid:2463827.
OpenUrl Abstract/FREE Full Text

[188] Cardin A D,

[189] Weintraub H J R

[190] ↵
Kubicek C P
(1982) Adv Biochem Eng Biotechnol 45:1–27.
OpenUrl

[191] Kubicek C P

[192] ↵
Pugsley A P
(1993) Microbiol Rev 57:50–108, pmid:8096622.
OpenUrl Abstract/FREE Full Text

[193] Pugsley A P

Main menu

User menu

Search

New Research In

Molecular characterization of the mycobacterial heparin-binding hemagglutinin, a mycobacterial adhesin

Abstract

MATERIALS AND METHODS

Bacterial Strains, Growth Conditions, and DNA Manipulations.

Production of Recombinant HBHA in E. coli.

Purification of Recombinant HBHA by Heparin-Sepharose Chromatography.

SDS/PAGE Analysis.

Protein Sequencing.

Determination of the Carbohydrate Content of HBHA.

Other Techniques.

RESULTS

Cloning and Sequencing of the M. bovis BCG HBHA-Encoding Gene.

Analysis of the HBHA Structural Gene.

Cloning and Sequence of the M. tuberculosis HBHA Structural Gene.

Production of HBHA in E. coli.

Evidence for Glycosylation of HBHA.

Susceptibility of Recombinant HBHA to Proteolytic Degradation.

Activities of Recombinant HBHA.

DISCUSSION

Acknowledgments

Footnotes

ABBREVIATIONS

References

Citation Manager Formats

You May Also be Interested in

Similar Articles

Articles

PNAS Portals

Information

Main menu

User menu

Search

New Research In

Physical Sciences

Featured Portals

Articles by Topic

Social Sciences

Featured Portals

Articles by Topic

Biological Sciences

Featured Portals

Articles by Topic

Molecular characterization of the mycobacterial heparin-binding hemagglutinin, a mycobacterial adhesin

Abstract

MATERIALS AND METHODS

Bacterial Strains, Growth Conditions, and DNA Manipulations.

Production of Recombinant HBHA in E. coli.

Purification of Recombinant HBHA by Heparin-Sepharose Chromatography.

SDS/PAGE Analysis.

Protein Sequencing.

Determination of the Carbohydrate Content of HBHA.

Other Techniques.

RESULTS

Cloning and Sequencing of the M. bovis BCG HBHA-Encoding Gene.

Analysis of the HBHA Structural Gene.

Cloning and Sequence of the M. tuberculosis HBHA Structural Gene.

Production of HBHA in E. coli.

Evidence for Glycosylation of HBHA.

Susceptibility of Recombinant HBHA to Proteolytic Degradation.

Activities of Recombinant HBHA.

DISCUSSION

Acknowledgments

Footnotes

ABBREVIATIONS

References

Citation Manager Formats

Sign up for Article Alerts

Jump to section

You May Also be Interested in

Similar Articles

Articles

PNAS Portals

Information